Molecular Oncology Testing in Resource-Limited Settings  by Gulley, Margaret L. & Morgan, Douglas R.




Molecular Oncology Testing in Resource-Limited Settings
Margaret L. Gulley* and Douglas R. MorganyFrom the Department of Pathology and Laboratory Medicine,* Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North
Carolina; and the Division of Gastroenterology, Hepatology, and Nutrition,y Vanderbilt University, Nashville, Tennessee
CME Accreditation Statement: This activity (“JMD 2014 CME Program in Molecular Diagnostics”) has been planned and implemented in accordance with the Essential Areas and
policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society for Clinical Pathology (ASCP) and the
American Society for Investigative Pathology (ASIP). ASCP is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this journal-based CME activity (“JMD 2014 CME Program in Molecular Diagnostics”) for a maximum of 48 AMA PRA Category 1 Credit(s). Physicians
should only claim credit commensurate with the extent of their participation in the activity.





Margaret L. Gulley, M.D.,
Department of Pathology and
Laboratory Medicine,
Lineberger Comprehensive
Cancer Center, University of
North Carolina, 913 Brinkhous-
Bullitt Bldg, Chapel Hill, NC
27599-7525. E-mail: margaret_
gulley@med.unc.edu.opyright ª 2014 American Society for Inve
nd the Association for Molecular Pathology.
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.jmoldx.2014.07.002Cancer prevalence and mortality are high in developing nations, where resources for cancer control are
inadequate. Nearly one-quarter of cancers in resource-limited nations are infection related, and molecular
assays can capitalize on this relationship by detecting pertinent pathogen genomes and human gene
variants to identify those at highest risk for progression to cancer, to classify lesions, to predict effective
therapy, and to monitor tumor burden over time. Prime examples are human papillomavirus in cervical
neoplasia, Helicobacter pylori and Epstein-Barr virus in gastric adenocarcinoma and lymphoma, and
hepatitis B or C virus in hepatocellular cancer. Research is underway to engineer devices that overcome
social, economic, and technical barriers limiting effective laboratory support. Additional challenges
include an educated workforce, infrastructure for quality metrics and record keeping, and funds to sustain
molecular test services. The combination of well-designed interfaces, novel and robust electrochemical
technology, and telemedicine tools will promote adoption by frontline providers. Fast turnaround is
crucial for surmounting loss to follow-up, although increased use of cell phones, even in rural areas,
enhances options for patient education and engagement. Links to a broadband network facilitate
consultation and centralized storage of medical data. Molecular technology shows promise to address
gaps in health care through rapid, user-friendly, and cost-effective devices reﬂecting clinical priorities in
resource-poor areas. (J Mol Diagn 2014, 16: 601e611; http://dx.doi.org/10.1016/j.jmoldx.2014.07.002)Supported by the University of North Carolina (UNC) Department of
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Disclosures: None declared.Molecular tests represent a powerful strategy for screening,
early detection, tumor classiﬁcation, and monitoring efﬁcacy
of intervention. Emerging technologies marry advanced
biochemical methods with innovative ﬂuidics and electronics
to address the need for robust, automated test systems. These
technologies are poised to facilitate a quantum leap forward
in cancer diagnostics in low- and middle-income countries.
In parallel with improved communication technology are
advances in biochemical sensors that make feasible measure-
ments of multiple DNA, RNA, or microRNA targets. Height-
ened capital investment in devices, often referred to as Lab on a
Chip, is streamlining specimen processing, biochemical anal-
ysis, and data manipulation.1 Before a new device can bestigative Pathology
.implemented, performance data must demonstrate that the test
system is analytically sound and clinically useful in the hands
of the professionals who use it.2 The bar for success might be
lessened by innovative internal quality control, automation
from input to reporting, and other engineering feats that pro-
mote good outcomes when implemented by minimally trained
Figure 1 Infection-related cancers comprise 23% of all cancers
worldwide. Oncogenic pathogens (A) are linked to higher cancer burden in
less developed regions of the world (B). Data are from de Martel et al.3
HTLV1, human T-cell lymphotropic virus 1.
Gulley and Morganworkers or patients. Thus, modern technology shows promise
to address gaps in health care through rapid, inexpensive,
automated test systems that identify and monitor the types of
neoplasia prevalent in resource-poor areas.
Cancer Burden in Resource-Limited Nations
Noncommunicable diseases are projected to become themajor
global health burden in the near term, with cancer accounting
for approximately one-quarter of this burden,3 ofwhich at least
one-third is preventable. The annual global incidenceof cancer
is projected to increase from12.7 to 22.2million by 2030,with
13.1 million expected deaths.4,5 More than two-thirds of the
burden will occur in low- and middle-income countries,
wherein seven cancer types (lung, colon, breast, stomach,
liver, cervical, and esophageal) account for nearly two-thirds
of incident cases (GLOBOCAN 2012, http://globocan.iarc.
fr, last accessed September 8, 2014). In the world’s poorest
countries, women are more than twice as likely to die of their
breast cancer, and children are up to ninefold less likely to be
cured of acute lymphoblastic leukemia.6,7
Cancer Linked to Infectious Disease
In developing nations, nearly one-quarter of cancers are
infection related,3 and four infectious agents account
for >80% of the burden: human papillomavirus (HPV),
Helicobacter pylori, hepatitis B virus (HBV), and hepatitis
C virus (HCV). Epstein-Barr virus (EBV) adds a signiﬁcant
burden in several areas of the world (Figure 1).
Approximately 30% of infection-associated cancers occur
in people <50 years. Compared to more developed regions,
less developed nations have more cancers of the stomach,
uterine cervix, and liver, all three of which are infection related
(GLOBOCAN 2012, http://globocan.iarc.fr, last accessed
September 8, 2014). Helicobacter pylori and EBV infection
are linked to gastric adenocarcinoma and lymphoma, whereas
HPV is uniformly found in cervical neoplasia. HBV or HCV
infections often predate hepatocellular carcinoma.
Research into the link between infection and cancer sheds
light on the mechanisms of oncogenesis. Interestingly, the
aforementioned infection-related cancers that are prevalent in
the developing world are the same three cancer types with the
most complex genomic signatures as elucidated by mutation
analysis.8 Mutations in infection-related cancer have been
attributed to the following: i) pathogen-induced effects, such as
heightened oxidation that damages DNA, ii) viral integration
events disrupting human genes or their regulatory factors, iii)
viral properties that prolong cell survival and resist apoptosis or
immune destruction, and iv) suppression of DNA repair.
There is an unmet need for affordable devices to detect
cancer-related infections. Such devices could capitalize on
the link between infection and cancer to assist in screening
and early diagnosis, tumor classiﬁcation, pathogen-targeted
therapy, and monitoring tumor burden over time.9602HPV
The HPV genome is present in virtually all cervical carci-
nomas. Because infection precedes malignancy, tests for the
relevant high-risk strains of HPV add value in cervical
neoplasia screening programs. Interestingly, the spectrum of
HPV strains in high-grade cervical lesions differs somewhat
by geographic region and by HIV status.10,11 These
population-speciﬁc differences emphasize the need to vali-
date genomic assays for each target population.
Rapid, low-cost devices are being developed to test for
HPV DNA and RNA.12e14 The careHPV test system (Qia-
gen, Hilden, Germany) was devised speciﬁcally for resource-
poor areas, and published data suggest that its performance is
similar to the US Food and Drug Administrationeapproved
HC2 test.14 The battery-powered bench-top instrument re-
quires neither electricity nor running water to perform hybrid
capture of RNA probes bound to high-risk HPV DNA ge-
nomes. The manufacturer states that the reagents are tolerant
of temperature swings that may characterize a rural labora-
tory having spotty electricity for refrigeration. The careHPV
test can be performed by minimally trained technologists atjmd.amjpathol.org - The Journal of Molecular Diagnostics
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potentially permitting same-day intervention for HPV-
positive patients.15 HPV tests may complement or replace
the visual inspection strategy that is currently favored over
cytology and over laboratory tests for cervical neoplasia
detection in many low-resource settings.14,16
High-risk HPV testing of a self-collected specimen, with
or without additional molecular tests of human genes, shows
promise to improve cost-effectiveness of screening pro-
grams in low-resource settings.17e20 High levels of HPV 16
DNA in mouthwash or tonsil swab samples likewise show
promise for identifying patients with infection-associated
oropharyngeal carcinoma.21
Helicobacter pylori
Gastric adenocarcinoma is the leading global cause of
infection-related cancer mortality and overall is the second
leading cause of cancer death, projected to increase to eighth
in all-cause mortality in the near term (GLOBOCAN 2012,
http://globocan.iarc.fr, last accessed September 8, 2014).
Helicobacter pylori infection is the strongest known risk
factor for gastric carcinogenesis. Risk depends not only on
bacterial genetics (eg, cagA and vacAs1m1 virulence factors)
but also on host genotypes [cytokine variants (eg, IL1B
511T)] and coinfections, which lend themselves to molecular
testing.22e25 Molecular test panels are being developed to
examine germline and somatic variants that, along with mo-
lecular evidence of H. pylori, EBV, and other infections,
could improve prediction of gastric cancer progression.24,26,27
Helicobacter pylori is also associated with gastric mucosa-
associated lymphoid tissue lymphoma (MALT), and eradi-
cating the bacteria via antibiotic therapy is curative in some
patients with lymphoma.28 Antibiotic drug selection is
improved by molecular testing of bacterial DNA.29 Clinical
trials examining efﬁcacy of antibiotics may beneﬁt from
molecular tests of bacterial DNA in biopsy, stool, or body
ﬂuids, including saliva.30e32 A creative strategy for specimen
collection from the upper gastrointestinal tract involves
swallowing a capsule attached to a ﬁxed string that is then
retrieved through the mouth for nucleic acid analysis.33
HBV and HCV
HBV and HCV infections are common and predispose to
hepatocellular carcinoma.34 Transfusion-mediated infection
remains a concerning means of spread for these and other
pathogens in countries lacking a centralized system for blood
collection and laboratory testing for transmissible agents.
Perinatal infection accounts for approximately half of the
burden among the 350 million people with chronic HBV
infection.35 Vaccination is recommended for HBV-related
cancer prevention, whereas treatment of HCV is associated
with reduced cancer risk.36 Viral genomes can be detected,
characterized, and monitored using molecular tests, such as
real-time quantitative PCR (qPCR).37,38 Proof of principle forThe Journal of Molecular Diagnostics - jmd.amjpathol.orga point-of-care device for HBVDNAwas recently reported.39
In this test system, an inexpensive microﬂuidic chip moves
DNA and wash/detection buffers through channels contain-
ing immobilized probe. Interestingly, the reporter probe was
designed to enzymatically convert sucrose into glucose so that
probe hybridization signals were measurable on the type of
personal glucometer that is commonly used at point of care.
EBV
EBV is deemed a group 1 carcinogen because of its putative
role in pathogenesis of endemic Burkitt’s lymphoma (BL),
extranodal natural killer/T-cell lymphoma (nasal type),
angioimmunoblastic T-cell lymphoma, aggressive natural
killer cell leukemia, immunodeﬁciency-related lymphoid
neoplasia including AIDS lymphoma, nasopharyngeal car-
cinoma, gastric adenocarcinoma, and Hodgkin lymphoma.
In each type of neoplasm, the viral genome is localized
within malignant cells, providing a convincing link between
infection and neoplasia that forms the basis for quantifying
tumor burden by blood EBV qPCR.9 Affected patients with
cancer tend to have high circulating EBV DNA loads that
predate clinical diagnosis of malignancy. Serial viral load
measurements reﬂect efﬁcacy of therapy.9
BL is an example of a cancer that is prevalent in resource-
limited areas of tropical Africa and for which molecular
tests can support a diagnosis. MYC translocation, clonal
IGH gene rearrangement, and EBV viral load tests have
been applied to blood, aspirate, or biopsy specimens sus-
pected to represent BL.40e43 Results of testing support a
clinical diagnosis of cancer pending deﬁnitive cytologic or
histological diagnosis that may be delayed because of
limited access to histopathology services.
HHV8
Another member of the human herpesvirus family, human
herpesvirus 8 (HHV8; alias Kaposi’s sarcomaeassociated
herpesvirus), is a group 1 carcinogen by virtue of its putative
role in causing primary effusion lymphoma and Kaposi’s
sarcoma. Endemic and HIV-associated Kaposi’s sarcoma are
prevalent in sub-Saharan Africa. Differentiation of Kaposi’s
sarcoma from clinical look-alikes, bacillary angiomatosis
(caused by Bartonella species) and pyogenic granuloma, was
recently achieved using a novel colorimetric nanoparticle
aggregation method targeting the DNA of each pathogen.44
In another advance, solar energy was used as the heat
source for a thermocycler that assisted, by a smartphone-
based camera, to detect ﬂuorescence, and an accompanying
app to analyze data was capable of detecting HHV8 DNA in
skin biopsy specimens of patients with Kaposi’s sarcoma.45
Tuberculosis
Tuberculosis is responsible for 1.7 million deaths per year.
Risk of lung cancer (especially adenocarcinoma) is increased603
Gulley and Morgan11-fold among patients with tuberculosis.46 Proposed mech-
anisms of mycobacteria-related carcinogenesis include long-
term immune stimulation (eg, tumor necrosis factor effect on
anti-apoptotic NF-kB signaling), neoangiogenesis, and DNA
damage from reactive oxygen species. Molecular tests can
detect and speciate mycobacteria and predict drug resistance to
assist clinicians in selecting rifampin, isoniazid, or second-line
medications.47 Cepheid was among ﬁrst device manufacturers
to develop a PCR test system speciﬁcally designed to be rapid
and user friendly in low-volume testing laboratories. The
performance of Cepheid’s Xpert MTB/RIF test has been
shown in tuberculosis-endemic regions to help guide appro-
priate therapy of affected patients and also to promote infec-
tion control in the larger community, leading to reduced
transmission rates and fewer drug-resistant organisms.48e51
HIV and Malaria
Immunodeﬁciency (eg, HIV infection or malaria-related
immune dysregulation) is a well-established predisposing
factor for selected forms of cancer, some of which, in turn,
harbor other viral genomes.52,53 HIV and malaria appear to
act indirectly to diminish T-cell defenses against viruses and
against tumor cells.54 Progressive HIV infection increases
risk of cancer up to 200-fold, whereas recent malaria
infection reportedly increases risk of BL by 21-fold.55
Patients with HIV or malaria remain at increased risk of
cancer, even with appropriate access to medical care.
The HIV epidemic markedly accelerated development of
molecular technologies and associated laboratory services.
The need for rapid HIV testing continues to drive im-
provements to laboratory infrastructure that is then applied
to diagnose other infectious diseases, cancer, or heritable
disease, and to provide pharmacogenetic predictions.
Recently, microﬂuidic chips were reported to detect HIV
and associated opportunistic infections (mycobacteria and
pneumocystis) by PCR or by isothermal loop-mediated
nucleic acid ampliﬁcation.56e58 A promising handheld de-
vice can detect and speciate malaria by isothermal rRNA
ampliﬁcation of 2 mL of blood without the need for
extraction.59 An optimized molecular method claims to be
2500-fold more sensitive than conventional microscopy for
malaria parasites.60 Cost savings accrue with proper diag-
nosis and treatment versus unnecessary spending associated
with misdiagnosis.61,62Multigene Test Panels Targeting Human and
Pathogen Nucleic Acid
The Cancer Genome Atlas project is a major step forward in
cataloging mutation patterns and gene expression proﬁles in
concert with traditional diagnostic histopathological analysis.
Results to date conﬁrm known cancer-related infections and
provide new insights into the genetic underpinnings of
neoplasia.63 Most tumors harbor many somatic changes that,604along with transcriptome and methylome data, reveal poten-
tial druggable pathways that can be explored in clinical trials.
Multigene test panels can characterize signaling pathways
driving tumor growth. A proof-of-principle study showed
that genotyping is achievable on fresh, frozen, or ﬁxed tis-
sue in just 70 minutes using an instrument platform that
performs automated extraction, followed by Invader chem-
istry,64 to query 13 mutations in KRAS, BRAF, and PIK3CA
genes.65 Another study detected heritable variants in cyto-
chrome p450 coding sequences to facilitate bedside clopi-
dogrel dosing.66 Although these technologic advances are
exciting, the particular somatic and heritable variants tar-
geted may be off target for the needs of resource-poor fa-
cilities, where downstream interventions are limited. A more
practical test panel in hospitals lacking on-site pathology
services might examine ﬁne-needle aspirate material from a
mass lesion to help distinguish infection from tumor,
pending send out for a pathologist’s deﬁnitive diagnosis
days to weeks later.67
Most of the technologies described herein are not yet
implemented because of an insufﬁcient evidence base and/
or inadequacy for particular local needs.68 Investment is
required to devise suitable genomic assays that answer
pertinent biological and medical questions in clinical trials
and ultimately in routine patient care. When applied in
resource-limited areas, one must consider the unique lo-
gistic, cultural, and technologic features that promote
success. As with all clinical research, multidisciplinary
collaboration is required to optimize assay design and to
ensure the study plan is ethical when offered to patients
with few alternatives for care. Judicious use of precious
resources is critical. Batch testing in a reference laboratory
is generally less expensive and more effective than is
point-of-care testing,69 although suitably designed test
systems could alter this equation. Even central labora-
tories will adopt one-off test systems when rapid turn-
around is required.Cancer Screening
There are marked global disparities in access to cancer
screening tests and programs. For cervical neoplasia,
screening programs are well established in many resource-
poor areas. Recent studies suggest that HPV DNA testing is
cost effective as a primary screening method on self-
collected specimens or on samplings gathered by health
care personnel.70,71 Nasopharyngeal carcinoma screening by
qPCR of EBV DNA in saliva or in nasopharyngeal brush-
ings shows promise as a means to identify tumor in high-
risk individuals.72,73 Screening for other cancers that are
prevalent in the developing world (lung, stomach, breast,
liver, colon, and esophagus) is in early stages of investiga-
tion to ﬁnd genomic signatures distinguishing precursor
lesions likely to act benign from those that are at risk of
progressing and, thus, require intervention (GLOBOCONjmd.amjpathol.org - The Journal of Molecular Diagnostics
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2014). A recent preventive health initiative in New Mexico
showed feasibility of biometric screening and education in a
community-based mobile unit.74 Endoscopic imaging tech-
nologies are advancing in parallel with molecular devices,
and the two strategies may synergize to better visualize le-
sions to collect by biopsy or brushing.Figure 2 Devices initially developed for military or aerospace use can
be re-appropriated for laboratory medicine. A portable thermocycler with
laptop computer interface, initially developed for military ﬁeld work, was
later adapted for health care settings. The military version, dubbed the
ruggedized advanced pathogen identiﬁcation device (RAPID), was
designed, in part, to examine environmental samples for biowarfare agents.
The device requires limited space and technologist expertise, while still
providing reliable real-time molecular results. Image used with permission
of BioFire Defense.Design of Molecular Devices for Resource-
Limited Settings
Government-sponsored research has devised test systems
for military and aerospace use, and some of these advances
have been adapted for beneﬁt of civilian health care fa-
cilities. For example, in the 1990s, the US government
funded Idaho Technologies (now BioFire Defense, Salt
Lake City, UT) to develop a briefcase-bound version of a
thermocycler that was later redesigned for clinical labora-
tory use (Figure 2). A modern Bioﬁre FilmArray System is
being developed to test 27 nucleic acid targets in 1 hour
with only 2 minutes of hands-on time.75 Even smaller
portable devices were designed for deployment by ﬁrst
responders in emergency situations.76 These devices tend
to operate without electricity and have ﬂexible test options
with barcode readers to ensure proper selection reagents
for each protocol. Reagents are freeze dried, which makes
them light weight to transport, and stable at room tem-
perature for 6 months. Software includes analysis and
archiving functions.77 Integrated test systems include pre-
analytic and postanalytic steps that are as important as the
hybridization phase for ensuring good outcomes.78
Although repurposing devices for resource-poor areas may
be helpful, the optimal device is built from the ground up to
meet the unique requirements of the locale and the intended
use. Although most of the world’s countries have at least one
state-of-the-art medical complex, some tests must be per-
formed in more remote facilities served by a meager work-
force, perhaps with limited access to refrigeration, electricity,
and potable water. Universally appealing device character-
istics include low-cost, robust, and sustainable systems that
are medically ﬁt for purpose. Table 1 lists features promoting
adoption of laboratory test devices, recognizing that various
medical providers have differing priorities.
Competition among vendors is a major driver of low cost
and innovation, as is trade policy improving access to
commercial products in the developing world. The recent
US Supreme Court ruling that isolated DNA does not
infringe on gene patents opens the door for molecular device
design on the basis of medical and public health needs
above costly legal quagmires.
Rapid, Inexpensive Molecular Technology
PCR is the mainstay of hybridization assays worldwide, but
emerging molecular technologies may be less expensive andThe Journal of Molecular Diagnostics - jmd.amjpathol.orgequally effective. A recent study of patients with hemor-
rhagic fever in Sudan showed that isothermal loop-mediated
ampliﬁcation (LAMP) was more rapid, less expensive, and
performed as well as RT-PCR for detecting viral RNA in
serum samples of patients with acute infection. The reaction
is performed in a 63C water bath rather than the more
expensive thermocycler needed for PCR.
Another isothermal nucleic acid sequence-based ampliﬁ-
cation (NASBA) technology is being adapted to quantify
HIV RNA and to predict drug resistance.79 NASBA is well
suited for RNA proﬁling because it skips the need for
reverse transcriptase used in RT-PCR. Expressed RNAs are
naturally more abundant than DNA, although RNA is also
more labile, thus generating the potential for specimen
degradation unless the test is done promptly or preservatives
are used.
Isothermal ampliﬁcation eliminates the need for costly
heating and cooling steps that characterize PCR. Instead,
enzymes achieve strand separation, and these enzymes (eg,
helicase) may be more tolerant of inhibitors than is the
polymerase used in PCR, potentially reducing the need to
purify analytes in crude specimens before hybridiza-
tion.64,80,81 LAMP technology typically relies on six
primers, two of which form stem loops that self-prime, and a
strand-displacing polymerase then ampliﬁes concatenated
products. The assay yields an insoluble end product that can
be quantiﬁed visually or in real time using a turbimetric
detector, potentially saving cost by eliminating expensive
ﬂuorochromes. An option for ﬂuorescent detection permits
multiplexing of LAMP assays in one reaction vessel.
LAMP assays have been developed to detect tumor-
speciﬁc RNA and also a range of microorganisms (bacteria,
mycobacteria, viruses, parasites, amoeba, and protozoa)
using handheld, battery-operated devices with disposable605
Figure 3 Electronic biosensors operate by electrochemical signal trans-
duction on hybridization to complementary target sequence in the patient
specimen. In this example, a hybridization-induced conformation change
increases the distance between the electrode and the reporter molecule,
which alters electron-transfer dynamics to generate a current in the elec-
trode. Billions of sensors can be placed on a single semiconductor chip for
simultaneous analysis of all relevant targets in human and pathogen ge-
nomes. System parts (chips, reagents, and detectors) are all inexpensive.
Table 1 Desirable Characteristics of Laboratory Test Systems
Medical performance
Reliable results (suitably sensitive, speciﬁc, linear, and
reproducible)
Informative for actionable medical decision making
Same-day turnaround time to minimize loss to follow-up
Administrative qualities
Low cost to establish and to maintain the test system
Straightforward training of staff and supervisory personnel
User-friendly interface
Intact supply chain for supplies and reagents
Option to use expired reagents with documented explanation
(eg, for training)
Simple equipment maintenance with reminders and record
keeping
Available service and repairs
Safe for patients and for testing personnel
Accessible where medically necessary
Quality assurance
Document and report provider’s ID, patient ID (option for
barcoding), specimen type, date/time collected and reported,
raw data, reportable result, interpretation, and comments
Automation to reduce risk of human error
Built-in quality checks with recorded results, such as
endogenous control
Contamination alert (eg, statistically unlikely series of results)
Flags to alert for malfunction, aberrancies, and suggested
corrective action
Barcoded supplies and reagent lot numbers recorded; alerts for
expiration dates
Proﬁciency survey availability
Educational materials for clinicians and for testing personnel
Environmental factors
Minimal requirements for continuous electricity, Wi-Fi access,
sterility, and clean water
Long shelf life under extreme conditions of transport and
storage
Disposal of toxic chemicals, biohazards, cartridges, and sharps
Durable hardware, and in some cases waterproof or portable
Lockable in a physical way and from a patient privacy
perspective
Gulley and Morganmicroﬂuidic cartridges.81e85 Open-source hardware, soft-
ware, and protocols are intended to spur further innovation.82
Technical reviews of LAMP and other isothermal ampliﬁ-
cation technologies were recently published.58,64,80 Thus far,
intellectual property concerns have hindered combining these
promising chemistries with specimen collection tools, ﬂu-
idics, and informatics modules required for a functional test
system.
Next-generation sequencing is exceptionally powerful in
its ability to identify genetic variants, although user-friendly
sequencing devices remain to be commercialized. The
technical costs of sequencing continue to plummet, but
implementation in health care remains in its infancy due to
the labor-intensive processes of preparing specimens and
interpreting sequence variants. As with all cancer genetic
tests, interpretation is done in the context of the clinical606question being posed and the input material on which each
test is performed (eg, tumor type, proportion of neoplastic
cells, and fresh versus ﬁxed tissue). Patient data are exam-
ined alongside multiple quality checks that reﬂect perfor-
mance of the test system and adequacy of patient material.86
Research is ongoing to construct databases linking sequence
variants to evidence of clinical actionability and improved
patient outcome.Chips, Assay Miniaturization, and Automation
Electronic sensors can detect DNA hybridization by its
effect on current ﬂowing through an electrode on a circuit
board (Figure 3). This technology, combined with minia-
turization (nanotechnology) and ﬂuidics, could provide cost
savings by using fewer and less expensive reagents, faster
thermocycling, and less labor when compared with tradi-
tional plate-based hybridization.87 On-chip ﬂuidics can
accommodate multistep processing, including cell separa-
tion, cell lysis, and nucleic acid puriﬁcation, before analysis.
Automation promotes standardization and reproducibility.
Several commercial test systems are capable of accommo-
dating small input volume for multiwell analysis using
disposable components.88,89 Interfaced barcode readers and
laboratory information systems promote specimen identiﬁ-
cation and data analysis for interpretation and reporting.Preservation of Nucleic Acid before Analysis
Abundant data conﬁrm that dried blood spots are amenable
for genotyping.41,43,90e93 Dried specimens stored or trans-
ported at ambient temperature represent a cost-effective
means of amassing specimens for batch testing. DNA,
RNA, and microRNA targets are reportedly recoverable
from ﬁlter paper on which blood or other body ﬂuids have
been dessicated. Alternative stabilizers have been describedjmd.amjpathol.org - The Journal of Molecular Diagnostics
Oncology Tests in Developing Nationsto promote specimen integrity between collection and
analysis.94e97
Human Resources
The single most important aspect of high-quality laboratory
service is competent personnel. This includes all personnel in
the chain from test order through collection, transport, anal-
ysis, interpretation, reporting, and downstream action. A
recent white paper from COLA highlights problems sur-
rounding tests done in poorly regulated health care envi-
ronments.98 Waived testing sites (ie, point-of-care sites) in
the United States indicated that 35% of personnel did not
properly record quality control data, and 31% did not main-
tain a log of tests performed. Poor preventive maintenance of
equipment can result in a variety of problems, including
contamination that may adversely affect sensitive molecular
tests. The ﬁndings highlight the potential gap between a well-
trained, well-supervised laboratory technologist and the re-
ality when other (well-meaning) health care providers
perform laboratory tests. It is, thus, recommended that testing
be done in a centralized laboratory, except when there is
medical need for rapid turnaround, to prevent loss to follow-
up, or when transport would compromise specimen integrity.
When less-experienced personnel are expected to perform
tests, it is important that test systems are engineered
accordingly to address likely errors in technique, interpre-
tation, or documentation. A supervisor should periodically
oversee the work of testing personnel (trust but verify) and
nurture those serving on the front lines who may otherwise
feel isolated. Continuing medical education motivates
workers to persist in and take pride in their specialized
work. Poor-quality test results not only harm patients but
ultimately undermine clinician’s conﬁdence in the utility of
laboratory tools, making it even more difﬁcult to establish
and maintain laboratory services. Software is available to
facilitate oversight of point-of-care testing.
It is difﬁcult to recruit and retain pathologists and tech-
nologists in developing countries. For example, in Honduras
there are only nine certiﬁed histotechnologists, none of
whom are positioned in rural areas. Stafﬁng is likely to get
worse in the coming decades due to a workforce shortage of
both pathologists and technologists. The looming crisis
must be addressed through training programs in developed
nations and in the developing world. A non-proﬁt organi-
zation, Pathologists Overseas, has a 25-year track record of
providing, advising, and promoting self-sustaining pathol-
ogy and laboratory services.99 Many other noteworthy
programs exist, such as those coordinated by the African
Society for Laboratory Medicine, the Pan American Health
Organization, the World Health Organization, the American
Society for Clinical Pathology, the American Society of
Cytopathology, the US and Canadian Academy of Pathol-
ogy, The Diagnostic Microbiology Development Program,
the Royal College of Pathologists, The International
Network for Cancer Treatment and Research, and theThe Journal of Molecular Diagnostics - jmd.amjpathol.orgCollege of American Pathologists Foundation. The pro-
grams are aimed at building local laboratory capaci-
ty.100e102 It is important to coordinate with in-country
leaders, particularly with the Minister of Health, to ensure
that effort is appropriate for local needs and that resources
are strategically allocated.
To promote capacity building, ideally local practitioners are
empowered for independence within the framework of
multinational regional networks (eg, Central America).102e105
The American Association for Clinical Chemistry offers an
online training program for point-of-care specialists. The
Association for Molecular Pathology helps arrange regional
chapters of molecular laboratory professionals. Much effort of
the aforementioned organizations is focused on educating
personnel working in central laboratories and academic cen-
ters, who, in turn, train others in the region. The College of
American Pathologists offers proﬁciency surveys that form
one component of quality assurance.
Telepathology
Telepathology encompasses the practice of pathology at a
distance. Remote interpretation of qualitative or quantitative
laboratory results is feasible, such as visualizing peaks on an
electropherogram or analyzing BAM ﬁles generated by
sequencing DNA of patients and associated controls.
Guidance from the Canadian Association of Pathologists
provides a framework for telepathology implementation and
validation.106
Telepathology assumes that an infrastructure exists to
perform the technical component of testing near the point of
care, and that technical components should be overseen by a
physician responsible for ensuring quality of transmitted
data or images. Broadband connection is available to only
one-third of the world’s population, although efforts are
underway to render access universal (eg, http://internet.org).
A large bandwidth is required for image transmission.
Telepathology is a mechanism for second opinion
consultation and for sharing case workload, reviewing
unusual cases for continuing medical education, and pro-
moting quality assurance. One concern about remote
consultation is the lack of consultant familiarity with local
medical practices and with regional diseases, such as
pertussis (whooping cough), tropical enteropathy, or
nutrient deﬁciencies. Video-conferencing is helpful for two-
way learning, devising and updating work plans, and
facilitating train the trainer programs.
Gopal et al107 recently described their experience estab-
lishing a histopathology laboratory in Malawi, including
digital image transmission of scanned slides to a consulting
pathologist at the University of North Carolina who reviews
ﬁndings with the primary pathologist in Malawi. The
establishment of new laboratory services is expensive and
requires multidisciplinary coordination (eg, with clinicians
and a wide range of staff). Medical equipment or supply
donations can be arranged by agencies such as Project607
Gulley and MorganC.U.R.E. (Commission on Urgent Relief and Equipment;
(http://www.projectcure.org), MedShare (http://www.Med
Share.org), MedWish (http://www.MedWish.org), or Cen-
tral American Medical Outreach (http://www.camo.org)
(websites were last accessed on September 8, 2014).
Information Systems
Same-day turnaround is often crucial for surmounting loss
to follow-up, although increasing availability of cell phones,
even in rural areas, provides better opportunity for patient
engagement. Text messaging is ubiquitous worldwide.
Smartphones are much more expensive but offer added
beneﬁts of global positioning system geotagging and inter-
faced biometric sensors with optional data upload to a
central databank.108,109 Patients and their providers can then
view serial data and receive customized notices or educa-
tional materials. An application for testing personnel (eg,
Radiometer America’s Avoid Errors application) contains
instructional videos on specimen collection, a competency
test, and tips to interpret ﬁndings or to troubleshoot prob-
lems. Connectivity to ﬁberoptic or mobile broadband ser-
vice not only offers a way to deliver health care but also to
facilitate epidemiological monitoring of emerging disease,
and to access consultants.75 Transcription errors are reduced
when data are automatically transferred.
The Computing For Good (http://limswiki.org/index.php/
C4G_BLIS, last accessed September 8, 2014) program at
Georgia Institute of Technology recently teamed with the
Centers for Disease Control and Prevention to ﬁeld-test an
open-source basic laboratory information system for com-
puter data entry and retrieval in laboratory settings.
Conclusion
Advances in molecular technology show promise to
improve cancer control in resource-limited nations through
rapid, informative, reliable, user-friendly, and cost-effective
laboratory tests. Much of the focus in developing nations is
on infection-related cancers because of their prevalence and
potential for cost-efﬁcient prevention, as well as the unique
opportunity to use the pathogen as a tumor marker pro-
moting diagnosis, monitoring, and targeted therapy.
Encouraging progress has been made in engineering devices
to overcome the economic and social barriers that often limit
effective laboratory support. Recent advances in technology
are yielding small, but powerful, instruments that, along
with accessible reagents, make feasible the types of mo-
lecular diagnostic systems that are suited to frontline
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